Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion
Transfusion · 2025
DOI: 10.1111/trf.18286 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Transfusion, 2025. Verfasst von Tamir Kanias und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Biotinylation, Erythrocytes, Erythrocyte Transfusion, Biotin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Red blood cell ( RBC ) biotinylation has increasingly become the preferred method for quantifying RBC post‐transfusion recovery ( PTR ). This study evaluated the feasibility of transfusing autologous RBCs labeled with biotin ( BioRBCs ) 48 h prior to transfusion. The rationale was to facilitate the distribution of BioRBC products from manufacturing sites to remote clinical sites. Study Design Leukocyte‐reduced RBC units from 12 healthy individuals were stored at 1–6°C for 42 days and biotinylated with two biotin densities (3 and 15 μg/ mL ) 48 and 4 h prior to transfusion. Each individual was transfused with 10 mL of each BioRBC preparation, after which BioRBC 20 h PTR and long‐term survival (30 and 90 days) were determined by flow cytometric analyses. Additional quality measurements included phosphatidylserine ( PS ) exposure on BioRBCs and in vitro metrics of hemolysis.
Results
RBC transfusion 48 h after biotinylation was not associated with altered BioRBC 20 h PTR or 30 and 90 day survival as compared with RBC transfusion 4 h after biotinylation (e.g., PTR 20 h: 85.7% ± 8.4% vs. 87.5% ± 7.3%; 48 and 4 h, respectively, p > .05). Similarly, no significant differences between the BioRBC groups were observed in BioRBC PS exposure at all time points. BioRBC long‐term survival, but not 20 h PTR , was negatively associated with donor hemoglobin (Pearson r = −0.71, p = .001) and osmotic hemolysis ( r = −0.783, p = .003). None of the participants developed antibodies against BioRBCs during the trial.
Conclusions
RBC biotinylation 48 h prior to transfusion does not compromise the quality and safety of BioRBC products. BioRBC long‐term survival can be used to identify donor characteristics that influence RBC lifespan in the circulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitalant Research Institute, Denver, Colorado, USA.
- Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Vitalant Innovation Center, Denver, Colorado, USA.
- Vitalant Research Institute, San Francisco, California, USA.
- Departments of Pathology and Laboratory Medicine, University of California, San Francisco, California, USA.
ORCID-Profile: Tamir Kanias, Kathleen Kelly, Philip J Norris
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kanias, T., George, G., Sekiya, J., Kelly, K., Stanley, C., Lee, D., Finlon, J., Rahman, M., Gehris, T., Bowen, D., Barton, M., Marschner, S., Berg, M. P., Norris, P. J., & Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P) (2025). Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion. Transfusion. https://doi.org/10.1111/trf.18286
Vancouver
Kanias T, George G, Sekiya J, Kelly K, Stanley C, Lee D, et al. Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion. Transfusion. 2025. doi:10.1111/trf.18286
BibTeX
@article{Kanias2025,
author = {Kanias, Tamir and George, Gemlyn and Sekiya, Joseph and Kelly, Kathleen and Stanley, Crystal and Lee, Deborah and Finlon, Jeffrey and Rahman, Maria and Gehris, Timothy and Bowen, Dylan and Barton, Michelle and Marschner, Susanne and Berg, Mary P and Norris, Philip J and Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P), Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P)},
title = {Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18286}
}
EUVIMED